Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations

Int J Pharm. 2022 Apr 5:617:121601. doi: 10.1016/j.ijpharm.2022.121601. Epub 2022 Feb 16.

Abstract

The study aimed to develop two types of dry powder inhaler (DPI) formulations containing glucagon-like peptide-1(7-36) amide (GLP-1): carrier-free (drug alone, no excipients) and carrier-based DPI formulations for pulmonary delivery of GLP-1. This is the first study focusing on the development of excipient free GLP-1 DPI formulations for inhaled therapy in Type 2 diabetes. The aerosolisation performance of both DPI formulations was studied using a next generation impactor and a DPI device (Handihaler®) at flow rate of 30 L min-1. Carriers employed were either a 10% w/w glycine-mannitol prepared by spray freeze drying or commercial mannitol. Spray freeze dried (SFD) carrier was spherical and porous whereas commercial mannitol carrier exhibited elongated particles (non-porous). GLP-1 powder without excipients for inhalation was prepared using spray drying and characterised for morphology including size, thermal behaviour, and moisture content. Spray dried (SD) GLP-1 powders showed indented/dimpled particles in the particle size range of 1-5 µm (also mass median aerodynamic diameter, MMAD: <5 µm) suitable for pulmonary delivery. Across formulations investigated, carrier-free DPI formulation showed the highest fine particle fraction (FPF: 90.73% ± 1.76%, mean ± standard deviation) and the smallest MMAD (1.96 µm ± 0.07 µm), however, low GLP-1 delivered dose (32.88% ± 7.00%, total GLP-1 deposition on throat and all impactor stages). GLP-1 delivered dose was improved by the addition of SFD 10% glycine-mannitol carrier to the DPI formulation (32.88% ± 7.00%-45.92% ± 5.84%). The results suggest that engineered carrier-based DPI formulations could be a feasible approach to enhance the delivery efficiency of GLP-1. The feasibility of systemic pulmonary delivery of SD GLP-1 for Type 2 diabetes therapy can be further investigated in animal models.

Keywords: D-mannitol carrier; Dry powder inhaler formulation; Glucagon-like peptide-1(7–36) amide; Glycine; Spray drying; Spray freeze drying.

MeSH terms

  • Administration, Inhalation
  • Aerosols
  • Diabetes Mellitus, Type 2* / drug therapy
  • Drug Carriers
  • Dry Powder Inhalers*
  • Excipients
  • Glucagon-Like Peptide 1
  • Humans
  • Particle Size
  • Powders

Substances

  • Aerosols
  • Drug Carriers
  • Excipients
  • Powders
  • Glucagon-Like Peptide 1